The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reporting.

Abstract

Although the use of chemotherapy and targeted therapy has improved the clinical benefit, progression-free survival, and overall survival of various cancers in recent years, old and new toxicities have limited their use. To balance the risk with the benefit of treatment, Common Toxicity Criteria and now Common Terminology Criteria for Adverse Events (CTCAE) have been used by the oncology community for more than 20 years to assess toxicity from cancer treatment. This article details the description and grading of cardiac toxicities reported in association with cancer treatment and the use of CTCAE to assess them.

DOI: 10.1016/j.hfc.2011.03.008

Cite this paper

@article{Hossain2011TheIO, title={The importance of clinical grading of heart failure and other cardiac toxicities during chemotherapy: updating the common terminology criteria for clinical trial reporting.}, author={Akm Hossain and Alice Chen and Percy S. Ivy and Daniel J. Lenihan and Jonathan R Kaltman and Wendy C Taddei-Peters and Scot C. Remick}, journal={Heart failure clinics}, year={2011}, volume={7 3}, pages={373-84} }